Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an oral formulation for oral use. It is employed to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients. GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kytril, a selective 5‑HT3 receptor antagonist, is indicated for conditions that trigger serotonin‑mediated nausea and vomiting.

Chemotherapy‑induced nausea and vomiting: prevents nausea and vomiting caused by cytotoxic chemotherapy. Postoperative nausea and vomiting: reduces incidence of nausea and vomiting after surgical procedures. Radiation‑induced nausea and vomiting: helps control nausea associated with radiation therapy.

Granisetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhoea - Abdominal pain

Serious or Rare Side Effects: - QT interval prolongation leading to cardiac arrhythmia - Severe allergic reactions such as anaphylaxis - Serotonin syndrome (rare) - Significant hypotension

Before prescribing Kytril, clinicians should consider several safety aspects.

Assess cardiac history: evaluate risk of QT prolongation. Review serotonergic medications: avoid concurrent use with other serotonin‑modulating agents. Monitor electrolyte balance: correct hypokalaemia or hypomagnesaemia. Use caution in hepatic impairment: dosage adjustment may be required. Store at room temperature: keep in the original container, protect from moisture.

Granisetron may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive antiemetic effect not recommended. - Drugs that prolong QT interval: increased risk of cardiac arrhythmia. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce granisetron effectiveness. - Anticholinergic agents: may exacerbate constipation.